Member Info for Jonahswell

Glad to see the change of leadership has given confidence back to buyers here after the disasterous RNS in January for holders like me at the time. Let's hope this price rise can be sustained through better sales to be reported for the rest of the year once they get a chace to put improvements in place.

Under Going Concern the company states:

'In assessing the appropriateness of adopting the going concern assumption, the Group has prepared a detailed budget ("the budget") for the period ending 31 December 2025 and a further forecast ("the forecast") for the period ending 30 June 2026.'

Trouble is these are not then presented as far as I can see.

Further the company also states under Provisions:

'At the reporting date, the Group has recognised a provision of £726,948 (2023: £nil) for minimum order penalties under its supply contracts. The provision represents penalties expected to be incurred due to not meeting the agreed-upon minimum order quantities during the financial year. The Group estimates that £286,948 of this provision will be paid within the next 12 months, with the remainder expected to be paid over the following 12 to 24 months.'

I'm not sure the update on progress of new studies/products offsets these negatives.

As a shareholder I will see how the market responds shortly before making any decisions

Lowest share price now since 2020. It's like Eroxon didnt exist. What a disaster for everyone invested here, including me. In some circumstances I might see this as a buying opportunity but not sure I can risk any more here.

Well that has screwed everyone who invested yesterday. What a badly timed announcement on the need for future fundraising. Anyone got an idea how long their current cash will last?

I'm invested here and so great to see the positive news this morning.

Based on the last couple of years we are due a trading update very soon and so hopefully that will confirm the great progress this company is making. As others have said the price was ranging 25-30 for most of 2024 and with nothing but good news coming through it is reasonable to think the unexplained drop from November will continue to be reversed over the next couple of months.

Invested here on the news in December of the Ph.3 trial starting towards FDA approval and therefore pleasantly surprised to see the recent rise on the 15th Jan despite no further news. Can only assume it was linked to increased buying that day as the news sunk in after the holidays. With the succes seen in many patients already and the planned rapid recruitment of 5000 patients leading to initial readout due Autumn 2025 I think we are going to see some exciting results, boosting the company's fortunes much sooner than is usual for other late stage clincal trials.

Invested here on the back of the recent trading update and so good to see the share price has continued to move up since then too. As the results were on track to be the best year yet before the aquisition of Bio-Vet I don't think it's unreasonable to see a further increase to 500+ leading up to the full year results in my opinion despite the dilution back in 2023.

I am invested here and so hope the recent sudden rise indicates a resolution of the dispute with Stalicla, leading to the payment of the outstanding $0.5m that was due after completion of the Ph1b trial in Aug 2023 and more importantly progress towards the $5.0m agreed on granting of an IND by the FDA for the next stage clinical trial. This company certainly needs to see progress and the cash IMO but unfortunately this isn't the first time a licensing partner just sat on an asset. Let's see what the next week brings.